Solid forms of nilotinib hydrochloride
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jun 28, 2016
Grant Date -
Oct 1, 2015
app pub date -
Oct 15, 2013
filing date -
Oct 15, 2012
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Disclosed are solid forms of Nilotinib hydrochloride and methods of preparation of various crystalline solvates of Nilotinib HCl including benzyl alcohol, acetic acid, propylene glycol, and isopropanol. Nilotinib HCl is a tyrosine kinase inhibitor used for the treatment of drug resistant chronic myelogenous leukemia (CML).
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully